Amerikanische Gesellschaft für Hirudotherapie

Prophylactic versus reactive leech therapy for venous congestion after fingertip replantation: A retrospective comparative study and literature review

Kameda Y, Motomiya M, Watanabe N, Ota M, Iwasaki N (2025) · JPRAS Open · n=25

RCT evidence detailTrial reference
GRADE LowCohort / case series
Sample size of this trial compared with other digit-replantation trialsElyassi AR 201430Kameda Y 202525Buntic RF 201019
This trial (highlighted) by sample size alongside other indexed digit-replantation trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, retrospective comparative study of two leech application strategies after fingertip replantation, with PRISMA-2020-guided literature review (Hokkaido Orthopaedic Memorial Hospital and Obihiro Kosei Hospital Hand Centre, Japan)
Sample size (n)
25
Intervention
Group B (n=13): prophylactic leech therapy two to three times daily from the early postoperative period, prior to clinical signs of congestion
Comparator
Group A (n=12): reactive leech therapy initiated only in response to clinical signs of venous congestion
Primary endpoint
Complete digital survival rate; secondary outcomes early postoperative complications, re-operation rate, transfusion requirement, and infection incidence
Primary result
Complete survival: 8/12 (67%) Group A vs 12/13 (92%) Group B; early postoperative complications: 6/12 vs 1/13 (p=0.030); re-operations: 6/12 vs 1/13 (p=0.030); transfusion only in 1 Group A patient (preexisting anemia); 1 Aeromonas infection; functional and aesthetic outcomes satisfactory in both groups
Follow-up duration
until full digital survival or revision surgery

Key Findings

  • First comparative study explicitly testing prophylactic vs reactive leech application timing for fingertip replantation
  • Prophylactic regularly-scheduled leech protocol associated with significantly higher complete digital survival (92% vs 67%)
  • Significantly fewer early postoperative complications (1/13 vs 6/12, p=0.030) and re-operations (1/13 vs 6/12, p=0.030) in prophylactic arm
  • Literature review combining the two groups with 129 digits from prior reports yielded overall survival 81% (124/154)
  • Authors recommend prophylactic regularly-scheduled leech protocol as a candidate standard for artery-only fingertip replantation given the favorable risk-benefit profile

Limitations

  • Retrospective non-randomized design - selection bias and confounding by indication likely
  • Very small sample (n=25 total) - severely underpowered for between-group statistical inference
  • Single 2-institution Japanese hand-surgery cohort - generalizability untested in other practice settings
  • No standardized definition of 'clinical signs of congestion' triggering reactive arm initiation
  • Literature review used PRISMA but few prior reports detailed specific leech protocols

Clinical Implications

Kameda 2025 is the first published study explicitly framing prophylactic vs reactive leech therapy as competing strategies in fingertip replantation. While the retrospective design and small sample limit causal certainty, the substantial absolute improvement in complete survival (25 percentage points) plus the lower reoperation and complication rates suggest that scheduled prophylactic leech application may outperform reactive application in this clinical context. For US hand surgeons, the trial supports consideration of prophylactic protocols, particularly in artery-only fingertip replantation where venous outflow re-establishment is the primary salvage challenge. The combined literature-review pool (n=154) provides the most current benchmark survival rate (~81%) for the indication.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.